Clinical characteristics of calcitonin-negative MTCs at the time of diagnosis
Age | Sex | RET mutation |
Size (cm) |
mLN (Number) |
N stage |
AJCC stage |
Ctn IHC |
Ctn (pg/mL) |
CEA (ng/mL) |
Clinical outcome |
---|---|---|---|---|---|---|---|---|---|---|
52 | F | - | 0.4 | 0 | 0 | I | (+) | 11.0 | 1.0 | No evidence of disease |
60 | M | - | 0.7 | 0 | 0 | I | (+) | 9.0 | 3.9 | No evidence of disease |
50 | F | - | 0.5 | 0 | 0 | I | (+) | 4.0 | 1.4 | No evidence of disease |
52 | M | Negative | 0.5 | 5 | 1a | III | (+) | 8.5 | 1.3 | No evidence of disease |
35 | F | Positive | 0.3 | 0 | 0 | I | (+) | 6.8 | 0.5 | No evidence of disease |
-: uninspected, AJCC: American Joint Committee on Cancer, CEA: carcinoembryonic antigen, Ctn: calcitonin, IHC: immunohistochemistry, mLN: metastatic lymph node